News

Engine Biosciences (Engine), a Singapore- and Silicon Valley-based biotechnology company pioneering precision medicine for cancer, announced a new partnership with the Experimental Drug…
Read More...

POXEL SA, a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic…
Read More...

ABL Bio Inc., a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, announced a worldwide licensing agreement…
Read More...

CAS, a division of the American Chemical Society specializing in scientific content and knowledge management, and Cleveland Clinic, an academic health system with a global footprint,…
Read More...

Ethris, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, and Lonza, one of the world’s largest contract development and manufacturing…
Read More...

Amgen announced that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA as the first and only treatment for adults living with Immunoglobulin G4-related disease (IgG4-RD).…
Read More...

Sangamo Therapeutics, Inc. announced it has entered into a license agreement with Eli Lilly and Company (“Lilly”), allowing Lilly to leverage Sangamo’s novel proprietary neurotropic…
Read More...

NBE Therapeutics (NBE) a wholly owned subsidiary of  Boehringer Ingelheim, officially opened its new ADC R&D facility in Basel. This milestone reinforces its commitment to…
Read More...

Neurona Therapeutics, a clinical-stage, privately-held, biotherapeutics company developing regenerative cell therapies for disorders of the nervous system, announced the successful…
Read More...

The US Food and Drug Administration (FDA) has granted orphan drug designation to rilzabrutinib, an investigational, novel, advanced, oral, reversible Bruton’s tyrosine kinase (BTK)…
Read More...

Novartis announced the US Food and Drug Administration (FDA) has granted accelerated approval for Vanrafia (atrasentan), a potent and selective endothelin A (ETA) receptor antagonist,…
Read More...

Flagship Pioneering announced an agreement between Pioneering Medicines, Flagship's in-house drug discovery and development unit, and Pfizer, to discover compounds which may lead to the…
Read More...

Astellas Pharma Inc. and Japanese Foundation for Cancer Research announced they have entered into a strategic collaboration to accelerate translational and clinical oncology research.…
Read More...

Pfizer Inc. announced that the European Commission (EC) has issued a decision amending the marketing authorization for ABRYSVO, the company’s bivalent respiratory syncytial virus (RSV)…
Read More...

Apellis Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review designation of the supplemental New Drug Application…
Read More...

AIRNA, a biotech company pioneering RNA editing therapeutics to transform the lives of patients with rare and common conditions, announced the closing of an oversubscribed $155 million…
Read More...

Amneal Pharmaceuticals, Inc. and Shilpa Medicare Limited announced the U.S. launch of BORUZU, a new presentation of bortezomib for ready-to-use subcutaneous administration or…
Read More...

Bavarian Nordic A/S announced that the U.S. Food and Drug Administration (FDA) has approved the freeze-dried formulation of JYNNEOS (Smallpox and Mpox Vaccine, Live, Non-replicating)…
Read More...

The US Food and Drug Administration (FDA) has approved Qfitlia (fitusiran), the first antithrombin-lowering (AT) therapy for routine prophylaxis to prevent or reduce the frequency of…
Read More...

AstraZeneca’s Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery…
Read More...